Pharmaceutical market & copycat innovation Germany| ��ƽ��

Share of market innovations and copycat innovations in the total sales of the manufacturing of pharmaceutical products in Germany from 2008 to 2023

Characteristic	Market innovations	Copycat innovations
2008	5%	15.1%
2009	4.3%	10.5%
2010	3.2%	12.8%
2011	5%	12.5%
2012	6.6%	9.4%
2013	7%	7.8%
2014	8%	8.2%
2015	9.4%	9.8%
2016	11.9%	10%
2017	9.3%	11.8%
2018	6.3%	12.9%
2019	6.1%	10.5%
2020	7.1%	13%
2021	5%	12.7%
2022	3.8%	14.5%
2023	3.2%	7.1%

Download

Source

Show detailed source information?

Already a member?

Source

Release date

January 2025

More information

Region

Germany

Survey time period

2008 to 2023

Special properties

Companies with at least five employees

Supplementary notes

The German innovation survey is carried out on behalf of the Federal Ministry of Education and Research (BMBF) by the Center for European Economic Research (ZEW, Mannheim) in collaboration with infas (Institute for Applied Social Science) and the Fraunhofer Institute for Systems and Innovation Research (ISI). The survey is aimed at all companies in Germany with at least 5 employees. The definitions and measurement concepts correspond to the international standards of OECD and Eurostat. The innovation survey is part of the Europe-wide innovation survey (Community Innovation Survey - CIS) coordinated by Eurostat every two years. All values are extrapolated to the population of companies with 5 or more employees in Germany. A total of more than 15,500 companies took part in the 2023 innovation survey (= 50% of the sample size), including 113 from the pharmaceutical industry.

Citation formats

In 2023, 3.2 percent of total sales of pharmaceutical products in Germany were market innovations. 7.1 percent were copycat innovations, which means that someone has adapted an already existing medicine or drug and used it in another way.